Primary atrophic rhinitis (ATR) is characterized by chronic progressive atrophy of the mucosa and greenish crusts responsible for foul odor (ozaena). A wide roomy nasal cavity resulting from bony (turbinates) resorption is a characteristic feature with abnormal patency.^[@bibr1-2473974X20949503]^ ATR is predominantly seen in women (6:1.5).^[@bibr2-2473974X20949503]^ It is common in tropical countries^[@bibr3-2473974X20949503],[@bibr4-2473974X20949503]^ and more prevalent with lower socioeconomic status and poor hygiene.^[@bibr5-2473974X20949503]^ The etiology is debatable. Polygenic inheritance is appreciated in 15% to 30%, in addition to autosomal dominant (67%) or recessive (33%)^[@bibr6-2473974X20949503]^ penetrance. Chronic bacterial infection is implicated,^[@bibr4-2473974X20949503],[@bibr7-2473974X20949503]^ particularly *Klebsiella ozaenae*.^[@bibr2-2473974X20949503]^ Developmental etiology with poor pneumatization of maxillary sinuses, congenitally spacious nasal cavities, or platyrrhinia has also been suggested.^[@bibr4-2473974X20949503],[@bibr5-2473974X20949503],[@bibr8-2473974X20949503]^ Nutritional deficiency (iron, fat-soluble vitamins, proteins),^[@bibr5-2473974X20949503],[@bibr9-2473974X20949503],[@bibr10-2473974X20949503]^ phospholipid deficiency,^[@bibr11-2473974X20949503]^ autonomic dysfunction,^[@bibr12-2473974X20949503]^ reflex sympathetic dystrophic syndrome,^[@bibr13-2473974X20949503]^ endocrinal (estrogen) imbalances,^[@bibr4-2473974X20949503],[@bibr14-2473974X20949503]^ allergy,^[@bibr2-2473974X20949503]^ immune disorders,^[@bibr15-2473974X20949503],[@bibr16-2473974X20949503]^ and biofilms have also been implicated. Two variants of ATR are described^[@bibr17-2473974X20949503]^: type I (50%-80%) characterized by endarteritis obliterans and periarteritis/fibrosis and type II (20%-50%) with capillary vasodilation. Ultrastructural changes are characterized by the absence of a mucus blanket, the loss of cilia, and squamous metaplasia of respiratory epithelium. Necrotizing infection and endarteritis cause underlying destruction and necrosis to form crusts that, when removed, result in epistaxis. Olfactory deficit and ozaena compromise social relations, and no study with validated tests has yet reported the olfactory status in ATR or its performance following treatment. Also, since there is no consensus regarding the most effective treatment protocol, this study aims to investigate not only olfactory status but also improvement with surgical and nonsurgical treatments.

Method {#section7-2473974X20949503}
======

This prospective study is based on 61 patients with ATR attending a university hospital of North India. Proper ethical clearance was obtained by the institutional review board of the King George's Medical University India (reference code 72nd ECM II A/P2; May 2015), and informed consent was undertaken. The inclusion criteria included wide nasal cavity, mucosal atrophy, and thick crust with or without epistaxis or ozaena. Those with secondary ATR, mental retardation, and pregnancy were not included. Apart from routine anamnesis, classical nasal endoscopy focused on mucosal atrophy, bony resorption, thick crust, fetid odor, and free mucous. Nasal swab and mucosal sample were obtained for microbiological and histopathologic examinations, respectively. The disease was defined arbitrarily as *mild-moderate* or *severe* ([**Table 1**](#table1-2473974X20949503){ref-type="table"}). A 2-dimensional estimate of bony absorption was attempted in 28 patients through Walters-Caldwell plain radiograms wherein a radiolucent area was estimated by superimposing graph paper bearing 1-mm^2^ squares. Before starting definitive treatment, all patients underwent olfactory assessment (in 59 cases) with the 12-item BSIT (Brief Smell Identification Test; Sensonics, Inc) per its standard operating manual, followed by 2-week antibiotic course (or longer until nasal culture became sterile for *K ozaenae*) in addition to nasal douche and cleaning. Amoxicillin with clavulanic acid was used consistently with addition of gentamycin (5 mg/kg of body weight) in case of severe prolonged infection or in cases of nasal myasis. The use of BSIT in an Indian population is validated, and due to the cost factor involved, UPSIT assessment (University of Pennsylvania Smell Identification Test) was not feasible. According to predefined normative values, BSIT scores were classified into normosmic (≥9), hyposmic (4-8), and anosmic (≤3). A BSIT score of 8 was arbitrarily labeled near normosmia but grouped with hyposmia for analysis.

###### 

Arbitrary Criteria Used for Defining Categories.

![](10.1177_2473974X20949503-table1)

  Categories                        Criteria
  --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease severity                  
   Mild to moderate                 Fetid odor, nasal dryness, occasional headaches, mucosal atrophy, thick crust, absence of free mucous
   Severe                           In addition to the above criteria, evidence of clinical/radiologic bony resorption, histologic metaplasia to squamous epithelium, or presence of maggots
  Improvement criteria              
   Subjective                       Permanent disappearance of odor, dryness sensation, sinogenic headache, nasal obstruction, epistaxis, thick crusts
   Objective                        Improvement in bacterial culture (*Klebsiella ozaenae*), endoscopic evaluation of transitional mucous, and histologic changes for recovery of cylindrical epithelium
  Categories of clinical response   
   Satisfactory                     Complete resolution of at least 5 of 6 subjective criteria plus improvement in at least 2 of the above objective criteria or a complete symptomatic resolution in the absence of objective assessment
   Unsatisfactory                   Resolution of \<5 subjective criteria and improvement in \<2 objective criteria or evidence of worsening

While most patients with predominantly mild-moderate disease refused to undergo surgery, the surgical arm focused mainly on the severe disease category. Despite surgical counseling, the preference of nonsurgical treatment by a majority of patients is not uncommon in India. Surgical candidates underwent modified Young's operation with continued multivitamin support and subsequent recannulation after 8 months. The modified Young's procedure permits a 1- to 2-mm residual aperture, as opposed to complete closure as in classical Young's surgery. The rationale of selecting the former was to allow some odorant stimuli into the nasal cavity to not hamper sensitivity of olfactory nerves by depriving them of any stimulus. The nonsurgical candidates were prescribed nasal lubricants with continued alkaline douche and multivitamins for 8 months. A fresh alkaline solution douche (NaCl \[36.7 g\] + Na~2~CO~3~ \[28.4 g\] + sodium diborate \[28.4 g\] in 280 mL of water) has been specially mentioned^[@bibr18-2473974X20949503]^ for ATR. Within 2 weeks following completion of 8 months of either treatment, repeat nasal endoscopy (for reappearance of free mucous), nasal swab examination, and olfactory assessment (BSIT) were undertaken. Hence the first BSIT assessment was carried out just before the start of the treatment, while the second was undertaken within 2 weeks following completion (mean, 8 days). Therefore, pretreatment BSIT score and difference of scores (pre- vs posttreatment) were 2 olfactory parameters used for analysis. Arbitrary subjective and objective criteria were considered to label the clinical improvement as either satisfactory or unsatisfactory ([**Table 1**](#table1-2473974X20949503){ref-type="table"}).

The following comparisons (analyses) were performed to better understand the disease process:

-   Mean BSIT score of severe versus mild-moderate category with a *t* test

-   Mean BSIT score of satisfactory versus unsatisfactory improvement with a *t* test

-   Mean difference in BSIT scores between satisfactory and unsatisfactory improvement with the *t* test

-   Mean radiologic atrophy (radiolucent area) of severe versus mild-moderate category with the *t* test (both radiography views were analyzed separately)

-   Mean difference in BSIT scores between severe and mild-moderate category with the *t* test

-   Mean age between severe and mild-moderate category with the *t* test

-   Two categories of disease severity were compared with 2 categories of clinical improvements via the 2 × 2 table and chi-square analysis with 1 degree of freedom.

-   Two categories of treatments were compared with 2 categories of clinical improvements via the 2 × 2 table and chi-square analysis with 1 degree of freedom.

-   The distribution of age groups was compared between severe and mild-moderate disease via the chi-square test with 5 degrees of freedom.

SPSS (v 21; IBM) was undertaken for analysis. The discrete/categorical variables were analyzed by chi-square test and the continuous variables by *t* test with appropriate tables. For estimating chi-square, the proportions in 2 columns (from 2 subsets) were tested for being similar (null hypothesis) or not. When 2 subsets showed similar proportions, the null hypothesis was accepted. Alternatively, the null hypothesis was rejected when the chi-square test statistic was larger than the tabulated value, wherein respective proportions differed and the row-wise category was independent of the column-wise category. The variance *S*^2^ was estimated as *S*^2^ = (*N*~1~-- 1)*S*~1~^2^+ (*N*~2~-- 1)*S*~2~^2^ / *N*~1~+*N*~2~-- 2, where *N*~1~ and *S*~1~ are the number of observations and the variance of first comparative set and *N*~2~ and *S*~2~ are the same for the second comparative set. The test of significance for variance *S*^2^ was measured as *t* = *X*~1~--*X*~2~ / √*S*^2^(1/*N*~1~+ 1/*N*~2~), where *X*~1~ and *X*~2~ are the means of the first and second sets of observations.

Results {#section8-2473974X20949503}
=======

A clear predominance of younger age and female (61%) sex was noted. The age varied between 18 to 72 years, and its distribution with sex is depicted in [**Figure 1**](#fig1-2473974X20949503){ref-type="fig"}. About a third of patients (31%) were \<30 years old (female, 52.63%) while another peak (31%) was between 45 and 55 years old (female, 73.68%). However, there was a clear dip in incidence in the fourth decade. With a single case in the eighth decade, any definite conclusion cannot be made. Importantly, extreme degrees of bony resorption with saddle nose and palatal perforation are still seen in India ([**Figure 2**](#fig2-2473974X20949503){ref-type="fig"}).

![Age distribution with sex variability. Frequency is charted on the *Y*-axis and age groups on the *X*-axis. The top-most line denotes overall distribution, whereas the middle and lower tracings denote distribution in females and males, respectively.](10.1177_2473974X20949503-fig1){#fig1-2473974X20949503}

![Bony resorption in advanced atrophic rhinitis resulting in (A) palatal perforation and (B) saddle nose.](10.1177_2473974X20949503-fig2){#fig2-2473974X20949503}

A comprehensive summary of all observations and parameters used in the analysis is presented in [**Table 2**](#table2-2473974X20949503){ref-type="table"}. Olfactory dysfunction was universally present. Anosmia and hyposmia were appreciated in 13 (22%) and 46 (78%) cases, respectively. The distribution of females and males with anosmia was 38.46% (n = 5) and 61.53% (n = 8) and with hyposmia 65.21% (n = 30) and 34.78% (n = 16). Only 5 hyposmic cases (8.47%) belonged to the near-normal category. Mild-moderate disease was seen in 16 (27.11%) and severe in 43 (72.88%). Male incidence was marginally more in the severe category (41.86%) than in the mild-moderate group (37.5%). Of the 55% of cases that showed *K ozaenae*, about two-thirds of the patients had a good response following the first course of antibiotic therapy, while the rest responded to the second course. Surgical treatment was undertaken in 33 cases (54%) and nonsurgical in 28 (46%). Clinical improvement could be assessed in 57 cases, as 4 were lost to follow-up. This was ranked satisfactory in 23 (40.35%) and unsatisfactory in 34 (59.64%). In terms of olfaction estimation, 2 cases were not consistent up-front, while 11 were lost to follow-up. [**Figure 3**](#fig3-2473974X20949503){ref-type="fig"} depicts the change in BSIT scores with surgical and nonsurgical treatment. While a mixed response was appreciated, the sample was not large enough to appreciate any significant trend. Statistical analysis after comparison of the various parameters is depicted in [**Table 3**](#table3-2473974X20949503){ref-type="table"} (elaborated in the [Supplemental Appendix](https://journals.sagepub.com/doi/suppl/10.1177/2473974X20949503), available online).

###### 

Comprehensive Summary of Clinical, Radiologic, and Olfactory Parameters Before and After Treatment.^[a](#table-fn2-2473974X20949503){ref-type="table-fn"}^
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                         Atrophy, mm^2^                                   
  ---- ---- --- ---- --- ---------------- ----- -------- ---------------- ---
  1    35   F   S    4   169              76    Sx       Satisfactory     7
  2    22   F   S    6                          Sx       No follow-up     
  3    23   F   S    1   156              32    Non-Sx   Satisfactory     2
  4    40   M   S    2   60               283   Sx       Unsatisfactory   2
  5    30   M   S    2                    99    Non-Sx   Satisfactory     5
  6    21   M   S    6   156              94    Non-Sx   Unsatisfactory   7
  7    25   F   MM   5                          Sx       Unsatisfactory   
  8    21   F   S                               Non-Sx   Unsatisfactory   8
  9    25   F   MM   3                          Sx       No follow-up     
  10   50   F   S                               Sx       Unsatisfactory   5
  11   55   F   S    4                          Non-Sx   Unsatisfactory   4
  12   60   M   S    1   153              13    Non-Sx   Unsatisfactory   7
  13   45   F   MM   5                          Sx       Unsatisfactory   5
  14   32   M   MM   4   67               21    Sx       Satisfactory     2
  15   70   M   S    3   101              53    Sx       Unsatisfactory   7
  16   56   M   S    6                          Non-Sx   Unsatisfactory   4
  17   45   F   S    4                          Non-Sx   Unsatisfactory   3
  18   20   F   MM   6                          Sx       Unsatisfactory   
  19   55   F   S    6                          Sx       Unsatisfactory   
  20   65   F   S    7                          Non-Sx   Satisfactory     6
  21   65   F   MM   4   244              77    Non-Sx   Unsatisfactory   1
  22   65   F   S    2                          Non-Sx   Satisfactory     2
  23   70   F        4                          Sx       Unsatisfactory   
  24   68   M   S    7                          Non-Sx   Unsatisfactory   6
  25   72   M   S    7                          Sx       Satisfactory     6
  26   45   M   MM   3   117              39    Sx       Unsatisfactory   5
  27   50   M   MM   2   187              39    Sx       Satisfactory     3
  28   50   F   S    3                          Sx       Satisfactory     
  29   30   F   MM   4                          Non-Sx   Unsatisfactory   4
  30   22   M   MM   6                          Non-Sx   Unsatisfactory   7
  31   42   M   S    1                          Non-Sx   Unsatisfactory   4
  32   30   F   S    5                    47    Non-Sx   Satisfactory     8
  33   50   F   S    6   222              88    Sx       Satisfactory     9
  34   20   M   MM   4                          Sx       No follow-up     
  35   60   M   S    4                    51    Non-Sx   Unsatisfactory   3
  36   18   M   S    5   76               73    Sx       Satisfactory     6
  37   45   M   S    8                          Sx       Satisfactory     5
  38   45   F   S    8                          Sx       Satisfactory     5
  39   40   F   S    2   188              132   Sx       Satisfactory     7
  40   45   F   MM   7   85               125   Non-Sx   Unsatisfactory   4
  41   60   F   S    5                          Sx                        
  42   30   F   S    8   64               48    Non-Sx   Unsatisfactory   5
  43   45   F   S    2                          Non-Sx   Unsatisfactory   5
  44   70   M   S    5   210              227   Non-Sx   Satisfactory     8
  45   60   M   S    6   86               82    Sx       Satisfactory     0
  46   65   F   S    3   376              199   Sx       Satisfactory     8
  47   50   F   MM   5                          Non-Sx   Unsatisfactory   3
  48   51   F   MM   3                          Sx       Satisfactory     3
  49   48   F   MM   4   127              66    Non-Sx   Satisfactory     2
  50   29   M   S    3                          Sx       Unsatisfactory   3
  51   60   F   S    4                          Sx       Satisfactory     4
  52   54   F   S    3   230              149   Non-Sx   Unsatisfactory   6
  53   52   M   S    7                          Sx       Unsatisfactory   
  54   30   F   S    3                          Non-Sx   Unsatisfactory   5
  55   22   M   S    4   135              53    Non-Sx   Unsatisfactory   6
  56   57   F   S    8   94               134   Non-Sx   Unsatisfactory   4
  57   42   F   S    3   45               90    Sx       Unsatisfactory   5
  58   35   F   S    7   252              140   Non-Sx   Unsatisfactory   4
  59   36   F   S    8                          Sx       Satisfactory     2
  60   19   M   S    7   91               63    Sx       Satisfactory     6
  61   20   M   MM   6                          Sx       Unsatisfactory   

Abbreviations: BSIT, Brief Smell Identification Test; F, female; M, male; MM, mild to moderate disease; non-Sx, nonsurgical treatment; OF, occipitofrontal view x-ray; OM, occipitomental view x-ray; S, severe disease; Sx, surgical treatment.

Blank cells indicate not available.

###### 

Statistical Analysis.
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  Comparable parameters                                                                            Variance *S*^2^                                               *t*                                                            Statistical significance
  ------------------------------------------------------------------------------------------------ ------------------------------------------------------------- -------------------------------------------------------------- -----------------------------
  Mean BSIT score of severe vs mild-moderate disease                                               4.01                                                          0.391                                                          No significant difference
  Mean BSIT score of satisfactory vs unsatisfactory improvement                                    4.16                                                          0.018                                                          No significant difference
  Mean DIFF-BSIT score of satisfactory vs unsatisfactory improvement                               7.75                                                          0.117                                                          No significant difference
  Mean radiologic (OM view) atrophy for severe vs mild-moderate disease                            6344.54                                                       0.345                                                          No significant difference
  Mean radiologic (OF view) atrophy for severe vs mild-moderate disease                            3858.38                                                       1.39                                                           No significant difference
  Mean age of severe vs mild-moderate disease                                                      244.775                                                       1.83                                                           Near-significant difference
  Mean DIFF-BSIT score of severe vs mild-moderate disease                                          7.5                                                           1.25                                                           No significant difference
  Chi-square analysis                                                                              χ^2^                                                          Tabulated                                                      
  Comparison between 2 categories of disease severities and 2 categories of clinical improvement   1.19^[a](#table-fn4-2473974X20949503){ref-type="table-fn"}^   3.84^[a](#table-fn4-2473974X20949503){ref-type="table-fn"}^    No significant difference
  Comparison between 2 treatment categories and 2 categories of clinical improvement               5.95^[a](#table-fn4-2473974X20949503){ref-type="table-fn"}^   3.84^[a](#table-fn4-2473974X20949503){ref-type="table-fn"}^    Significant difference
  Comparison of age groups among those with severe vs mild-moderate disease                        7.42^[b](#table-fn5-2473974X20949503){ref-type="table-fn"}^   11.07^[b](#table-fn5-2473974X20949503){ref-type="table-fn"}^   No significant difference

Abbreviations: BSIT, Brief Smell Identification Test; DIFF-BSIT, mean difference in BSIT scores; OF, occipitofrontal view x-ray; OM, occipitomental view x-ray.

*df* = 1.

*df* = 5.

![Changes in Brief Smell Identification Test (BSIT) scores with surgical and nonsurgical treatments.](10.1177_2473974X20949503-fig3){#fig3-2473974X20949503}

Discussion {#section9-2473974X20949503}
==========

Olfaction was universally deranged in ATR. Bimodal age presentation and female predominance were noted. Better clinical improvement was significantly associated with surgical treatment, suggesting the latter as better modality over nonsurgical treatment. However, the degree of clinical improvement did not show any relation with up-front severity of disease. A near-significant association of age with severity of disease did not, however, reveal significance when analyzed for different age groups. Baseline olfactory status or change in olfaction following treatment did not show any relationship with severity of up-front disease or clinical improvement criteria. Finally, radiologic atrophy showed no significance with severity criteria.

The main strength of this study is the first-time use of a validated psychophysical scale (BSIT) in assessment of olfactory dysfunction of ATR and olfaction with disease severity and the effect of nonsurgical and surgical management on olfaction. Despite limited cases, our sample is still the largest. Better results may theoretically be obtained by comparing different etiologic subsets independently, but this again may be difficult for this rare disease. Moreover, there is potential bias for allocating the severe category to the surgical arm; hence, it is possible to better appreciate large subjective improvement as compared with smaller change in the mild-moderate category. A proper randomized controlled trial may resolve this issue. In the absence of high-resolution imaging due to financial constraints, plain radiography seems very crude to conclude a nonsignificant association. In addition, histologic assessment of ultrastructural mucosal changes was not possible in all cases. Furthermore, this study did not include any validated quality-of-life assessment mainly due to the fact that none to date has been developed for ATR exclusively and using the existing ones may not truly reflect this particular disease per se. Hence, subjective and objective parameters, though arbitrary but specific to ATR, were selected to score improvement. Here it is important to mention that the arbitrary definitions cited in [**Table 1**](#table1-2473974X20949503){ref-type="table"} were based on our institutional experience for \>6 decades (with S.C.M. being faculty since 1966). Selected criteria are most essential (per the literature) and seem quite practical to be adapted in countries with limited resources where ATR is more prevalent. With only basic objectivity criteria, the current scoring algorithm (satisfactory/unsatisfactory) is easy to reproduce and likely to help in validation. Assessment following antibiotic course (before starting definitive treatment) was purposely not undertaken, since the aim was to assess comprehensive improvement at the end of treatment. Ignoring the presence of bacteria other than *K ozaenae* is another limitation of this study. In addition, the duration of antibiotic therapy was not uniform in this cohort. The autoimmune workup was also not undertaken in any patient, owing to cost factor.

Anosmia in ATR is well appreciated in the literature^[@bibr1-2473974X20949503],[@bibr13-2473974X20949503],[@bibr19-2473974X20949503]^ and reported to occur between 40% and 91%.^[@bibr20-2473974X20949503]^ Anosmia may be due to nerve inflammation, atrophy of olfactory mucosa, derangement in the central olfactory pathway, or reduced air entry due to crusts. The loss of sensory nerves of the nasal cavity reduces local sensations, and the cumulative effect makes the patient unaware of foul nasal discharge. In addition, flies (*Chrysomyia* sp) may enter and lay eggs in the nose, resulting in nasal myasis eroding the surrounding structures. This is now uncommon in India. Only a single study^[@bibr21-2473974X20949503]^ to date has measured olfaction in ATR (N = 75), and that too was by a nonvalidated technique based on 4 colorless liquid odors, wherein 10% revealed normal olfaction while 90% showed abnormality---of which 30% had mild loss, 24% severe dysfunction, and 36% complete anosmia. A single study^[@bibr22-2473974X20949503]^ on secondary ATR based on validated olfactory tests revealed dysfunction in 7 of 9 patients who underwent total bilateral inferior turbinectomy.

The age distribution in our population revealed 2 peaks at comparatively younger age groups, while the elderly population was relatively less affected. These peaks roughly correspond to puberty and menopause. The therapeutic effect of estrogen on 1 subset of ATR has already been mentioned,^[@bibr17-2473974X20949503]^ suggesting some possible endocrinal influence. The genetic factors may also play some role in preferential age presentation. Although radiologic assessment of atrophy was undertaken by 2 persons independently, the nonsignificant association with severity of disease is not unexpected, given the small sample, nonuniform quality, and difficulty in deciding areas of atrophy. Hence, radiography can best help in documenting maxillary sinusitis or bony erosion (myasis).

The lack of significant objective recovery of olfaction may be due to the predominance of patients with severe disease (73%) that may have significantly affected olfactory functions; moreover, the follow-up period may have been too short to assess any neurologic recovery. Since baseline olfactory status did not always reflect up-front clinical severity, it may be possible that olfactory functions are sensitive enough to be affected much earlier. This, however, does not support the fact that all those with near-normal olfaction (BSIT score = 8) had severe disease on presentation, and the olfactory scores, despite surgical management, eventually worsened. Also since the recovery of olfaction was no different between mild-moderate and severe disease, it is possible that other influences (eg, genetic, metabolic, endocrinal, autoimmune, degenerative, inflammatory) may be more important than simply mucosal atrophy, osteocartilaginous resorption, or anatomic obstruction induced by dried crusts in so-called advanced disease. Again, since recovery of olfaction did not show any relation with clinical improvement, it is assumed that clinical improvement occurs early independent of olfactory recovery and that the olfactory functions are either quite slow to recover or do not recover fully after being irreversibly damaged. Hence, it seems evident that the pattern of olfactory dysfunction in ATR is quite different from the usual clinical parameters, and while the latter may add to the dysfunction of former, both progress and regress independently. Good clinical improvement may be a prerequisite for improvement in olfaction, but that in turn does not guarantee satisfactory olfactory recovery. Since surgical treatment was significantly associated with better clinical improvement, it is likely more effective in resolving local conditions with associated recurrent infections (and not necessarily olfaction) as seen with empty nose syndrome. Near-total surgical closure (modified Young's) is likely to prevent mucosal desiccation and secondary bacterial invasion, as opposed to medical management with an open nasal aperture. The various shades of olfactory losses do suggest some ongoing neuropathy, and surgical closure to facilitate clinical improvement will provide a favorable environment for olfactory recovery and even prevent further insult induced by recurrent infections, dryness, or crusting. Otherwise, surgery per se may not have any direct effect on improvement of olfaction, with dysfunction being a combined systemic and environmental effect. Long-term studies need to be undertaken to establish the same.

As a nonuniform outcome of antibiotics on ATR is reported in immigrants with different backgrounds,^[@bibr23-2473974X20949503]^ resistant infection may account for nonsatisfactory clinical improvement, as seen in 59.64%. Its incurable yet nonfatal status was well addressed by Fraenkel in 1876.^[@bibr24-2473974X20949503]^ The ongoing postinflammatory fibrosis and existing endarteritis or periarteritis^[@bibr25-2473974X20949503]^ may resist recovery of olfactory functions. Since bacteria superinfects the underlying immunocompromised (susceptible) nasal environment, olfactory dysfunction detected at an initial stage may be considered a surrogate marker of clinical worsening. Studies involving early ATR are required to establish the same, and unfortunately, our study could recruit only full blown established cases as the patients in India usually present late in the course of illness..

The conclusion regarding relevant clinical care based on this study is straightforward. Since the onset and recovery of olfactory and clinical parameters in ATR occur independently (except for being indirectly related) it is likely that even after complete clinical recovery of ATR, the residual olfactory deficit may reflect a fragile residual state with a potential for repeat worsening of the clinical condition and a possibility of bacterial superinfection. Hence, it is important to continue proper lubrication, local care, and conservative management with repeated follow-up olfactory assessments to determine either a true improvement or further deterioration in fragile residual state depending on the underlying immunologic state. It is the latter subset that needs particular attention. Larger studies are needed to better understand the relationship of olfaction with multiple etiologic factors to enhance the quality of life of patients of low socioeconomic status in resource-poor countries .
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